Paulo Verardi, a virologist at the University of Connecticut, said that the Russian vaccine against coronavirus infection Sputnik V, due to its advantages, will play an important role in the fight against the pandemic around the world. TASS reports.
“Unlike other recombinant COVID-19 vaccines based on the Sputnik V adenovirus vector, it is based on a prime-boost immunization scheme using two different recombinant vectors: first [human] adenovirus 26 [serotype], and then adenovirus 5- go [serotype], ”the specialist said. Prime-boost immunization refers to a two-stage vaccination: the first dose triggers the immune response, and the second boosts it.
Verardi noted that such a scheme “does not allow the immunity developed against the first vector to interfere with the second dose of vaccine, which is a clear advantage.”
Earlier in the medical journal Lancet, data appeared that the results of the third phase of clinical trials of the Russian Sputnik V vaccine demonstrated 91.6% effectiveness against coronavirus. 19,866 people took part in testing the vaccine.
Sputnik V was developed by the Russian Gamaleya Research Center for Electrochemistry and became the world's first officially registered vaccine against coronavirus. Later, the Russian Ministry of Health registered another drug – EpiVacCorona, developed by the Vector Center of Rospotrebnadzor.
